The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

2 Visningar
administrator
administrator
07/18/23

Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

  • Kategori

Visa mer

0 Kommentarer Sortera efter

Inga kommentarer hittades

Facebook-kommentarer

Strax